Zurich Cantonal Bank
AMLX icon

Zurich Cantonal Bank’s Amylyx Pharmaceuticals AMLX Stock Holding History

Zurich Cantonal Bank’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-35,877
Closed -$433K – 2596
2025
Q4 		$433K Buy
+35,877
New +$487K ﹤0.01% 1870

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Zurich Cantonal Bank's AMLX Position: Q2 2026 in Review

Zurich Cantonal Bank reduced its Amylyx Pharmaceuticals (AMLX) stake by 58% in Q2 2026, selling an estimated $369K and leaving 16,956 shares worth $305K. The position accounts for ﹤0.01% of the portfolio, ranked #2176.

Zurich Cantonal Bank first reported a position in AMLX in Q1 2023 and has held it in 10 quarters since. The position peaked at $567K in Q1 2026. 206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • Zurich Cantonal Bank held 16,956 shares of Amylyx Pharmaceuticals worth $305K as of Q2 2026.
  • Zurich Cantonal Bank sold 23,834 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $369K.
  • Amylyx Pharmaceuticals made up ﹤0.01% of Zurich Cantonal Bank's portfolio in Q2 2026, its #2176 holding.
  • Zurich Cantonal Bank first reported a position in Amylyx Pharmaceuticals in Q1 2023 and has held it in 10 quarters since.
  • Zurich Cantonal Bank's Amylyx Pharmaceuticals position peaked at $567K in Q1 2026.
  • 206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Zurich Cantonal Bank's 13F filing for Q2 2026, filed 12 Aug 2026.